The clinical and theranostic values of activated leukocyte cell adhesion molecule (ALCAM)/CD166 in human solid cancers

Yang, Yiming, Sanders, Andrew J. ORCID: https://orcid.org/0000-0002-7997-5286, Dou, Q. Ping, Jiang, David G., Li, Amber Xinyu and Jiang, Wen G. ORCID: https://orcid.org/0000-0002-3283-1111 2021. The clinical and theranostic values of activated leukocyte cell adhesion molecule (ALCAM)/CD166 in human solid cancers. Cancers 13 (20) , 5187. 10.3390/cancers13205187

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

Activated leukocyte cell adhesion molecule (ALCAM), also known as CD166, is a cell adhesion protein that is found in multiple cell types. ALCAM has multiple and diverse roles in various physiological and pathological conditions, including inflammation and cancer. There has been compelling evidence of ALCAM’s prognostic value in solid cancers, indicating that it is a potential therapeutic target. The present article overviews the recent findings and progress in ALCAM and its involvement in cancer, with a primary focus on its clinical connections in cancer and therapeutic values.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Additional Information:	This article is an open access article distributed under the terms and con‐ ditions of the Creative Commons At‐ tribution (CC BY) license (http://crea‐ tivecommons.org/licenses/by/4.0/).
Publisher:	MDPI
ISSN:	2072-6694
Date of First Compliant Deposit:	17 October 2021
Date of Acceptance:	14 October 2021
Last Modified:	10 Jun 2023 13:32
URI:	https://orca.cardiff.ac.uk/id/eprint/144891

Citation Data

Cited 1 time in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item